Eligibility creep: A cause for placebo group improvement in controlled trials of psoriasis treatments

Journal of the American Academy of Dermatology

Volumn 57, Issue 6, 2007, Pages 972-976

  Hick, Jeff ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE SEVERITY; DRUG RESPONSE; HUMAN; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RETROSPECTIVE STUDY; SCORING SYSTEM;

ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; CONTROLLED CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULIN G; PATIENT SELECTION; PLACEBO EFFECT; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 36048963546     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.08.008     Document Type: Article

References (12)

1. National Institutes of Health. Elicidation of the underlying mechanisms of placebo effect. Available from: URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-AT-02-002.html. Accessed June 12, 2007.
2. Garris P.A., Kilpatrick M., Bunin M.A., Michael D., Walker Q.D., and Wightman R.M. Dissociation of dopamine release in the nucleus accumbens from intracranial self-stimulation. Nature 398 (1999) 67-69
3. de la Fuente-Fernandez R., Ruth T.J., Sossi V., Schulzer M., Calne D.B., and Stoessl A.J. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293 (2001) 1164-1166
4. Feldman S.R. Placebo effects: artifact of modern clinical trial conduct. J Dermatol Treat 14 (2003) 70
5. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356 (2000) 385-390
6. Mease P.J., Gladman D.D., Ritchilin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H.S., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arthritis Rheum 52 (2005) 3279-3289
7. Gladman D.D., Mease P.J., Ritchlin C.T., Choy E.H.S., Sharp J.T., Ory P.A., et al. Adalimumab for long-term treatment of psoriatic arthritis. Arthritis Rheum 56 (2007) 476-488
8. Antoni C.E., Kavanaugh A., Kirkham B., Tutuncu Z., Burmester G.R., Schneider U., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis. Arthritis Rheum 52 (2005) 1227-1236
9. Leonardi C.L., Powers J.L., Matheson R.T., Goffe B.S., Zitnik R., Wang A., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
10. Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 (2006) 598-606
11. Chaudhari U., Romano P., Mulcahyb L.D., Dooley L.T., Baker D.G., and Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 357 (2001) 1842-1847
12. Koshi E.B., and Short C.A. Placebo theory and its implications for research and clinical practice: a review of the recent literature. Pain Pract 7 (2007) 4-20